Bright Minds Biosciences Inc. Common Stock
DRUGBright Minds Biosciences Inc. (DRUG) is a biotechnology company focused on developing psychedelic-inspired medicines for mental health and neurological disorders. The company leverages innovative compounds and research to create therapies aimed at providing novel treatment options for conditions such as depression, anxiety, and trauma-related disorders.
Company News
Bright Minds Biosciences (NASDAQ: DRUG) successfully closed a public offering of 1.945 million common shares at US$90 per share, raising US$175.05 million in gross proceeds. The company plans to use the net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, Prader-Willi Syndrome, and BMB-105, along with R&D and ...
Bright Minds Biosciences priced an upsized public offering of 1,945,000 common shares at $90 per share for gross proceeds of $175.05 million. The company plans to use net proceeds to fund clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome, as well as phase 1 trials for BMB-105. The offering is expected ...
Bright Minds Biosciences strengthened its scientific advisory board with four experts in Prader-Willi Syndrome, launching a new investigational drug program targeting the rare genetic disorder. The company will evaluate existing and new treatment candidates, with initial Phase 1 studies focusing on safety and tolerability.
Bright Minds Biosciences will present at the Guggenheim Healthcare Innovation Conference and Jefferies Global Healthcare Conference in November 2025, and has granted stock options to directors, officers, and consultants.
Firefly Neuroscience, a Nasdaq-listed AI company, announced its Q3 2024 financial results and provided updates on its partnerships with pharmaceutical companies like Bright Minds Bioscience, Novartis, and Takeda to advance its Brain Network Analytics (BNA) technology for neurological and mental disorder treatments.
